Cordis Corporation
From the first guidewire to the first drug eluting stent, for over 60 years Cordis has remained at the heart of cardiovascular innovation. Cordis is again at the forefront of transformation in the cardiovascular space, leveraging internal development, partnership with the CordisX innovation incubator and targeted acquisitions of industry-disrupting technology. These innovations, brought to market with the strength of Cordis’ global footprint and operations, seek to transform the interventional space through enhanced clinical outcomes, customer-centric services, and impactful educational platforms – doubling-down on our commitment to the interventional community. Cordis will Go Beyond, to relentlessly pursue our dedication to transform cardiovascular care. This channel shares content only for Health care professionals (HCPs)www.cordis.com
12
MENTIONS
5
EPISODES
5
PODCASTS
Search complete. 12 mentions across 5 episodes found for "Cordis Corporation".
Sep 15, 2026
Amin AstaniGUEST
So for that reason, I use the forefrench.
Amin AstaniGUEST
I use a Merit, not Merit, a Cordis Tempo.
Amin AstaniGUEST
It's called burn, but it's not 45 degrees, actually 90 degrees.
Amin AstaniGUEST
It's extremely stiff.
Kavi KrishnasamyHOST
Yeah, for me, the 1.7 Asahi, as we said, and then I tend to use a C2, 4-fringe C2 glide cath.
Kavi KrishnasamyHOST
If I feel like I'm losing torque ability, then I'll switch it to a 5-fringe C2 glide cath to just go a little bit bigger.
Kavi KrishnasamyHOST
But it's nice to know about that Cordis cath.
Kavi KrishnasamyHOST
I'll have to try that as well.
Lisa Camooso MillerHOST
Will, when we talk about making examples clearer for members of Congress, uh, Brody and I today are your audience and are curious, are there examples in the industry that you can point to that can help us understand the kind of impact that you're making?
Will DunhamGUEST
One such example is a company called Cordis.
Will DunhamGUEST
Uh, it's a medical device company.
Will DunhamGUEST
It's about seventy years old, and in its early days, it was very, very innovative with patent after patent.
Will DunhamGUEST
In its middle years, it kind of lost its way, and it, it, it really got lost in a couple big conglomerates.
Will DunhamGUEST
Um, and recently, one of our big members, Hellman & Freeman, based out in San Francisco, carved Cordis out of that big conglomerate, and they did something really interesting.
Will DunhamGUEST
They gave them an infusion of capital specifically for innovation because they knew that innovation was in this company's DNA, and the result has been really extraordinary.
Will DunhamGUEST
Last year, one of the biggest advances in cardiovascular health came out of Cordis.
Brian BrownHOST
What is it, Steve?
Bill DixonHOST
Cordis has had that forever.
Brian BrownHOST
No, Steve-
Steve HeoGUEST
No, it's by Medtronic
Steve HeoGUEST
What?
Bill DixonHOST
I hate them.
Brian BrownHOST
You like the, you like the extruded plastic of Cordis? What are you talking about?
Bill DixonHOST
I use, I use Bos- we use Boston.
Scott NelsonHOST
And again, we'll link to it in the write-up on MedTiter, but it's calahealth.com, C-A-L-A health.com.
Scott NelsonHOST
So with that said, Deanna, let's jump to the first topic, which I want to cover, is kind of this overarching concept of building a medtech business, right? And you mentioned that you'd spent some time at other large strategics, you know, Cordis J&J during kind of the heyday of the drug-eluting stint stint wars, so to speak, and then kind of building a startup inside Boston Scientific.
Scott NelsonHOST
And so as you think about how you're trying to build the culture and push the company forward at Cala, are there a few like key things that you've taken with you, you know, from those experience at Boston Scientific and J&J Cordis and other strategics, or maybe even things that you're trying to avoid, right, as you're developing kind of the startup mentality at Cala?
Deanna HarshbargerGUEST
Yeah, I mean, I do think there are a lot of parallels.
Deanna HarshbargerGUEST
And I think that surprises many people because when you think about working in a large strategic and then going to a startup and saying what's really different, I think it is decisions that are magnified because the stakes are high at the startup.
speaker_1UNKNOWN
This incredibly tough, inert ceramic layer acts as a vault door, completely isolating the toxic niddle atoms from the body's tissues and bloodstream.
DavidHOST
That passivation layer paved the way for the ultimate biomedical game changer, the 1999 Cordis SMART stent, which was the first FDA-approved nitinol stent.
speaker_1UNKNOWN
This device relies purely on the shape memory effect intersecting with human biology.
DavidHOST
How does it work?